MedTrace Logo

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

NCT01724554 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-05-22

No results posted yet for this study

Summary

The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or Proliferative Diabetic Retinopathy (PDR).

Conditions

  • Central Retinal Vein Occlusion
  • Proliferative Diabetic Retinopathy

Interventions

DRUG

Intravitreal Aflibercept Injection

Aflibercept administered to the eye intravitreally either every month or every other month.

Sponsors & Collaborators

Principal Investigators

  • Jeffrey S Heier, MD · Ophthalmic Consultants of Boston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01724554 on ClinicalTrials.gov